Show simple item record

dc.contributor.authorAydemir, Işıl
dc.contributor.authorTürköz Uluer, Elgin
dc.contributor.authorKorkmaz, Oya
dc.contributor.authorTuǧlu, Mehmet İbrahim
dc.contributor.authorİnan, Sevinç
dc.date.accessioned2021-04-26T07:19:19Z
dc.date.available2021-04-26T07:19:19Z
dc.date.issued2020en_US
dc.identifier.citationAydemir, I., Türköz Uluer, E., Korkmaz, O., Tuǧlu, M. İ. ve İnan, S. (2020). Adjuvant effects of chemotherapeutics and metformin on MFE-319 endometrial carcinoma cell line. Romanian Journal of Morphology and Embryology, 61(3), 707-714. https://doi.org/10.47162/RJME.61.3.09en_US
dc.identifier.issn1220-0522
dc.identifier.issn1582-4926
dc.identifier.urihttps://doi.org/10.47162/RJME.61.3.09
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6769
dc.description.abstractWe aimed to investigate the cytotoxicity of Metformin, Cisplatin, and Paclitaxel on MFE-319 endometrial carcinoma cell line using 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and immunocytochemistry assays. Half maximal inhibitory concentration (IC50) doses of three drugs alone and in the dual combinations were applied to the cells. Immunocytochemical method was performed for the cell survival and for phosphatidylinositol 3-kinase (PI3K), phosphorylated extracellular regulated kinases (pErk)-1/2, Akt-1, phosphorylated Akt (pAkt)-1/2/3 cell growth markers and angiogenic vascular endothelial growth factor (VEGF). Immunoreactivities were evaluated using H-score and analyzed using the one-way analysis of variance (ANOVA) test for statistics. It was found that these drugs caused a decrease in the immunoreactivities of these markers. Particularly, dual combination of Paclitaxel and Cisplatin decreased the immunoreactivities of PI3K, pErk-1/2, Akt-1, and pAkt-1/2/3. Cisplatin and Paclitaxel were more effective than Metformin; on the other hand, Metformin has been shown to enhance the efficacy of these two drugs. In vitro or in vivo further studies are needed to investigate the efficacy of these three drugs via PI3K/Akt signal pathway.en_US
dc.language.isoengen_US
dc.publisherEditura Academiei Romaneen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectCisplatinen_US
dc.subjectEndometrial Carcinomaen_US
dc.subjectMetforminen_US
dc.subjectPI3K/Akten_US
dc.subjectPaclitaxeen_US
dc.titleAdjuvant effects of chemotherapeutics and metformin on MFE-319 endometrial carcinoma cell lineen_US
dc.typearticleen_US
dc.relation.journalRomanian Journal of Morphology and Embryologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Histoloji ve Embriyoloji Ana Bilim Dalıen_US
dc.authorid0000-0003-2923-5869en_US
dc.identifier.volume61en_US
dc.identifier.issue3en_US
dc.identifier.startpage707en_US
dc.identifier.endpage714en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.47162/RJME.61.3.09en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess